EC expands approval of Reblozyl to first-line treatment of anemia in MDS

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Commission expanded the indication of Reblozyl (luspatercept) to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low, and intermediate-risk myelodysplastic syndromes. This approval of Reblozyl covers all EU member states.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login